Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer
The DOI matches its Crossref record.
Abstract
Purpose: Tumor response is considered a surrogate marker of survival. We investigated whether tumor response based on computed tomography (CT) scan or whole-body [18 F]fluorodeoxyglucose positron emission tomography (PET) scan after neoadjuvant chemotherapy for resectable non–small-cell lung cancer (NSCLC) is prognostic of survival. Patients and Methods: Two consecutive phase II clinical trials were jointly analyzed. Patients underwent CT and PET scans before and after completion of neoadjuvant chemotherapy, followed by surgery. Results: Eighty-nine patients were included. Patients with a partial or complete response based on Response Evaluation Criteria in Solid Tumors categories (n = 33) had a better overall survival than those with stable or progressive disease (n = 56; median survival time, not reached v 36 months, respectively; P = .04). Of all patients, those with response in the highest quartile had 1- and 2-year survival rates of 100% and 81%, respectively, compared with 77% and 61%, respectively, among patients in the lowest quartile. However, on the basis of visual analysis of PET scan, patients with a metabolic response (n = 28) had no significant difference in survival compared with patients without response (n = 61; median survival time, 35.6 months v not reached, respectively; P = .94). In addition, on the basis of a semiquantitative analysis of PET scan, using at least 30% reduction in tumor metabolism as a response (n = 59), we also found no significant difference in survival among those with or without response. Conclusion: Among patients with resectable NSCLC treated with neoadjuvant chemotherapy, we found no evidence that tumor response by PET scan after chemotherapy is prognostic of survival; however, response by CT scan was associated with better survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Special Treatment Issues in Non-small Cell Lung Cancer
Kozower, B. D., Larner, J. M., Detterbeck, F. C., & Jones, D. R. (2013) · Chest · doi:10.1378/chest.12-2362 · Cited by 372
William, W. N., Pataer, A., Kalhor, N., Correa, A. M., Rice, D. C., Wistuba, I. I., Heymach, J., Lee, J. J., Kim, E. S., Munden, R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182774108 · Cited by 138
“Similarly in other tumor types, Choi and colleagues demonstrated that GIST tumors treated with imatinib were more accurately assessed with small CT changes in tumor size or density rather than standard RECIST criteria, while Chun and colleagues found that colorectal liver metastases were more accurately assessed with…”
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy
Weissferdt, A., Pataer, A., Vaporciyan, A. A., Correa, A. M., Sepesi, B., Moran, C. A., Wistuba, I. I., Roth, J. A., Shewale, J. B., Heymach, J. V., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.003 · Cited by 113
Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings
Kumar, V., Nath, K., Berman, C. G., Kim, J., Tanvetyanon, T., Chiappori, A. A., Gatenby, R. A., Gillies, R. J., & Eikman, E. A. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318279ffdf · Cited by 76
Self-citation
Metadata
- Authors
- Tanvetyanon, T., Eikman, E. A., Sommers, E., Robinson, L., Boulware, D., & Bepler, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-01
- Volume
- 26
- Issue
- 28
- Pages
- 4610-4616
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120997966
- Cited by
- 66
- References
- 0
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2008.16.9383
- The paper
- Tanvetyanon, T., Eikman, E. A., Sommers, E., Robinson, L., Boulware, D., & Bepler, G. (2008). Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.16.9383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.